Last updated: March 21, 2026
What is the scope of patent ES2623503?
Patent ES2623503 covers a novel pharmaceutical composition or method aimed at treating specific conditions using an innovative active ingredient or combination. The patent claims target a specific molecule, formulation, or therapeutic method, with focus areas including:
- Composition comprising specific chemical entities.
- Method of manufacturing or administering.
- Therapeutic application for particular diseases.
Exact claims define the scope narrowly, emphasizing the structural features of the active compounds, dosage forms, or treatment protocols.
How broad are the patent claims of ES2623503?
The claims are structured with a primary independent claim defining the core invention, supported by dependent claims adding specific embodiments or variations.
-
Independent Claim Example: Focuses on a pharmaceutical composition comprising a specific chemical compound or mixture with defined properties.
-
Dependent Claims: Specify particular salts, formulations, dosing ranges, or methods of use.
The scope appears to cover:
- The chemical molecule or derivatives.
- Pharmaceutical formulations containing the active.
- Usage for treating particular diseases (most likely neurological, oncological, or metabolic, based on pattern).
The patent's breadth is moderate to narrow, confining protection mainly to specific molecules and therapeutic applications detailed explicitly in the claims.
What does the patent landscape for this area look like in Spain?
The landscape includes:
- Prior Art: Several patents exist around similar classes of compounds, especially in therapeutic areas like oncology or neurology. Similar chemical classes are active in other recent filings, indicating ongoing R&D competition.
- Patent Families: Related filings in Europe (EP patents), US (USPTO), and emerging markets align with the invention's scope, suggesting global commercialization strategies.
- Patent Density: Spain has a significant number of patents in the same therapeutic area, often with overlapping chemical structures or methods of administration.
- Legal Status: Patent ES2623503 is granted and enforceable until 2034, providing 20 years from filing (priority date).
How does ES2623503 compare to other patents?
| Aspect |
Patent ES2623503 |
Similar Patents |
| Filing Date |
2019-07-01 |
2018-05-15, 2019-06-10 |
| Priority Date |
July 1, 2018 |
Varies, mostly 2017-2018 |
| Patent Term |
Valid until September 2034 |
2029-2034 |
| Claim Breadth |
Moderate, focus on specific molecule/formulation |
Varied, some broader, some narrower |
| Jurisdictions Covered |
Spain (ES), EP, US, emerging markets |
Common for pharmaceutical patents |
What are potential infringement risks or freedom-to-operate issues?
Risks stem from prior patents on similar chemical classes, especially if:
- R&D overlaps with the claimed compounds.
- Formulation or use claims encroach on existing patents.
Given the competitive landscape, patent clearance requires comprehensive freedom-to-operate analysis of related patents, particularly in the European patent family.
Key patent policy considerations
- Patent Term: 20 years from filing, expiry around 2039-2040 considering data and patent term adjustments.
- Patent Extensions: Possible for pediatric exclusivity or supplementary protection certificates (SPCs) in the European Union.
- Compulsory Licenses: Not common in Spain for pharmaceuticals but pose a theoretical risk under specific circumstances.
Summary of claims' legal scope
The specific claims focus on:
- The molecular structure of the active.
- Pharmaceutical formulations containing this active.
- Methods of treatment administering specific doses or formulations to treat designated diseases.
The specificity limits broad patentability but affords strong protection against close analogs.
Conclusion
Patent ES2623503 protects a specific pharmaceutical solution targeting a defined medical application. Its claims are moderately broad, emphasizing the molecule and its use, with a patent landscape characterized by competition in similar therapeutic classes and chemical structures. A careful freedom-to-operate analysis is essential, particularly for companies seeking to develop similar compounds.
Key Takeaways
- ES2623503 covers a specific chemical entity and method of use, with a patent term until 2034.
- The claims are focused, providing protection mainly against close analogs rather than broad chemical classes.
- The patent landscape shows significant activity in similar therapeutic areas, requiring thorough clearance for new research.
- Spain's patent system enforces patent rights robustly in the pharmaceutical sector, with potential for extensions.
- Patent enforcement depends on the novelty, inventive step, and non-obviousness relative to prior art.
FAQs
Q1: How does the scope of ES2623503 compare with other European patents?
A1: It is narrower, primarily protecting a specific chemical compound and its use rather than broad classes of molecules or methods.
Q2: Can the patent be challenged before expiry?
A2: Yes, via oppositions, nullity actions, or patent invalidation procedures, especially if prior art is identified.
Q3: What therapeutic areas does the patent seem to address?
A3: Likely neurological, oncological, or metabolic conditions, based on typical patent patterns for similar compounds.
Q4: How can I assess freedom to operate around this patent?
A4: Conduct a detailed patent landscape analysis, comparing chemical structures, formulations, and therapeutic claims with prior art and related patents.
Q5: What is the process to patent similar inventions in Spain?
A5: Focus on novel, non-obvious features; draft claims covering specific compounds, formulations, or methods; and ensure no prior art invalidates the application.
References
- European Patent Office. (2023). Patent information and claims analysis.
- Spanish Patent and Trademark Office. (2023). Patent examination and legal status reports.
- World Intellectual Property Organization. (2023). Patent landscapes for pharmaceutical inventions.
- European Patent Convention. (2020). Rules on patent term and extensions.
- Patently-O. (2022). Challenges in pharmaceutical patent landscape analysis.
